Inside the $617B Biotech Race: Can Science Extend Life?
Billions are flowing into anti-ageing biotech as the longevity market races toward $617 billion by 2045. Here's what the science can (and can't) yet deliver.
Growing old has always been inevitable. Increasingly, it is also becoming an investment thesis. Over the past two years, biotech firms, pharmaceutical giants and a small club of billionaires have poured tens of billions of dollars into an audacious goal: not just treating the diseases that come with age, but slowing or even reversing ageing itself. New industry projections put the global longevity market on track to hit $617 billion by 2045, a figure large enough to exceed what the world currently spends on cancer and heart disease treatment combined.
A Longevity Market Racing Toward $617 Billion
The funding numbers tell the story of a sector moving from fringe curiosity to a serious capital market. Investment in longevity biotech climbed from around $4.7 billion in 2024 to a record $18.4 billion in 2025, and 2026 has already added roughly $12.1 billion more, pushing cumulative investment past $30 billion. Analysts tracking the space project peak annual sales of about $230 billion from therapies already on a realistic regulatory path, with another $173 billion a year potentially unlocked if regulators create dedicated approval routes for “gerotherapeutics” — drugs aimed at ageing itself as the root cause of multiple diseases, rather than treating each illness on its own. The first such approvals could arrive as early as 2035.
Big Pharma and Big Tech Are Both In
What was once the territory of eccentric biohackers has become a magnet for institutional money. Eli Lilly backed a $435 million funding round for NewLimit, a cell-reprogramming startup, valuing the company at $3.1 billion. Takeda has struck a partnership with Insilico Medicine worth up to $600 million. Tech billionaires, including Amazon founder Jeff Bezos, have bankrolled ventures such as Altos Labs, built around the idea that ageing cells can be nudged back to a younger state. Even established blockbuster drugs are being repositioned for the longevity market: GLP-1 medicines like semaglutide, already famous for weight loss, are now being marketed by Novo Nordisk and Eli Lilly as cardiovascular protection for older patients, backed by trial data showing a meaningful drop in heart attack, stroke and cardiovascular death among high-risk patients.
The Science Behind the Hype
Most of this research centres on a handful of biological mechanisms: clearing “senescent” or zombie cells that accumulate with age, epigenetic reprogramming that nudges old cells back toward a youthful state, and metabolic pathways already targeted by decades-old, inexpensive drugs like metformin and rapamycin. The appeal isn’t purely marketing — these mechanisms are documented in animal studies, where lifespan extension has been repeatedly demonstrated in mice and other model organisms.
Can Humans Actually Live Longer?
The harder question is whether any of this translates to people. No drug has yet been approved anywhere in the world specifically to treat ageing, largely because regulators such as the US FDA do not recognise old age itself as a disease with a measurable clinical trial endpoint. Scientists writing in recent commentary have repeatedly urged caution, noting that much of the consumer-facing anti-ageing industry — supplements, at-home biomarker tests, biohacking regimens — is running well ahead of the clinical evidence. What is being sold today as “reversing” ageing remains, in most cases, unproven in large, controlled human trials.
What Comes Next for the Longevity Market
That gap between capital and proof is exactly what the next decade is meant to close. With regulatory pathways for gerotherapeutics potentially opening by 2035, and pharmaceutical giants now willing to underwrite expensive, large-scale research, the field may finally get the rigorous human trials needed to separate genuine breakthroughs from wellness marketing. Whether the $617 billion longevity market ends up buying humanity extra years of healthy life, or simply funds an extraordinarily expensive set of experiments, is a question that the next decade of clinical data — not investor enthusiasm — will have to answer.
